United States: FDA Issues Revised Draft Guidance On Disclosures Of Risk Information In Consumer-Friendly Print Advertisements And Promotional Labeling

The U.S. Food and Drug Administration (FDA) recently released its Revised Draft Guidance entitled "Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Human Prescription Drugs" (Draft Guidance).  The Draft Guidance significantly revises the FDA's January 2004 draft guidance on the brief summary requirement for disclosures in consumer-directed print advertisements and also covers promotional labeling.  In the revised Draft Guidance, the agency strongly recommends the use of either a Drug Facts Box or a series of questions and answers for displaying risk information in consumer-directed print advertisements and promotional labeling in order to improve patient comprehension of important product-related information.  According to the FDA, these "research-tested" formats are designed to be an alternative to the use of lengthy and technical risk information that currently appears in traditional print advertisements and promotional labeling.

Scope of the Draft Guidance

The Draft Guidance applies to prescription drug and biological product print advertisements and promotional labeling, if such materials are directed to consumers.  The Draft Guidance does not apply to promotional materials directed at health care professionals, or to radio, television or broadcast advertisements.  Additionally, the Draft Guidance does not address risk information included in the main portion of the advertisement or promotional labeling.  Rather, the Draft Guidance focuses on a new "consumer brief summary."

A New Approach to the Content and Format of Brief Summary and Adequate Directions for Use Requirements: The Consumer Brief Summary

The Draft Guidance discusses how manufacturers, packers, distributors and those working on their behalf (firms) traditionally approach the "brief summary" and "adequate directions for use" requirements contained in the Federal Food, Drug, and Cosmetic Act in the context of consumer-directed prescription advertisements and promotional labeling pieces.  The brief summary requirement mandates the disclosure of each side effect, warning, precaution and contraindication from the prescription drug's labeling in drug advertisements.  Currently, firms typically meet the brief summary requirement by providing the entire risk-related portion of the FDA-approved package insert.

The adequate directions for use requirement provides that prescription drug promotional labeling materials distributed by or on behalf of a firm must contain adequate information for use and additional labeling information as set forth in 21 C.F.R. § 201.100(d).  Firms generally fulfill the adequate directions for use requirement by including the full package insert.

In the Draft Guidance, the FDA sets forth its strongly preferred streamlined approach for fulfilling the brief summary and adequate directions for use requirements.  The FDA refers to its recommended approach of combining the information in the brief summary and adequate directions for use requirements as the "consumer brief summary."  The FDA's suggested approach allows firms to provide consumers with the same content in print advertisements and promotional labeling pieces.

The FDA states that it "does not intend to object if a firm does not include 'each specific side effect and contraindication'" from the package insert in the brief summary.  Similarly, if firms follow the Draft Guidance, the FDA states that it "does not intend to object for failure to include the entire [package insert] to fulfill the requirements of [21 C.F.R. §] 201.100(d) for consumer-directed promotional labeling pieces."  

The Draft Guidance discusses three key aspects of the consumer brief summary: 

  • Language and readability
  • Content
  • Format

Language and Readability Recommendations

The Draft Guidance was informed by studies of how well consumers absorbed the detailed information contained in the package insert, which was the means of conveying the required information in the traditional approach.  The studies found that this lengthy technical information was difficult for consumers to understand.  In order to create advertisements and promotional labeling pieces that are more consumer friendly, the FDA recommends that firms take the following steps:

  • Write for varying levels of literacy skills
  • Avoid technical, scientific and medical jargon
  • Use a conversational tone
  • Use signals, such as headlines and subheadings
  • Repeat the use of logos and branded colors from the main body of the advertisement in the consumer brief summary
  • Maximize background or white space to improve readability
  • Select font sizes and styles based on readability
  • Use text boxes with headings, bullets and other attention-drawing mechanisms

Content Recommendations

The consumer brief summary should focus on the most significant clinical information and the most serious and common risks.  To determine which serious and common risks to include in the consumer brief summary and which to omit, the Draft Guidance recommends that firms take the following steps:

  • Review risk information in FDA-approved patient labeling and Medication Guides
  • Include information about relevant drug risks that does not appear in the patient labeling
  • Examine the criteria for selecting risk information for the Highlights of Prescribing Information for risk topics to add to the consumer brief summary, but provide more detailed and material information than the information that appears in the Highlights
  • Display information in the consumer brief summary in an order substantially similar to the Highlights of Prescribing Information

According to the Draft Guidance, the following information should be included in the consumer brief summary:

  • Boxed Warning (if applicable to the particular drug or biologic)
  • All contraindications
  • From the Warnings and Precautions sections of the package insert, the most clinically significant information, including 
    o Information that would affect a decision to prescribe or take a drug
    o Whether monitoring or laboratory tests are needed during treatment
    o Special precautions not included in other parts of the package insert
    o Measures that patients should take to prevent or mitigate harm

The FDA also recommends that the consumer brief summary include the following:

  • The most frequently occurring adverse reactions for each indication for which the product is being promoted, listed in the same order as in the package insert
  • Serious adverse reactions and other important adverse reactions, unless mentioned elsewhere
  • Material information regarding risks, including severity or early warning signs of risks
  • The indication for the use being promoted and information relevant to each indication being promoted
  • Clinically significant drug interactions
  • Topics consumers should discuss with their health care providers
  • Information relating to special populations of concern based on the drug's safety profile
  • A reminder that the information in the summary is not comprehensive
  • A suggestion that consumers speak to their health care provider or pharmacist
  • A toll-free number or website where consumers can find the FDA-approved labeling

The Draft Guidance also outlines topics that can be excluded from the consumer brief summary:

  • Information that appears in the Directions for Use section
  • Dosage, administration and clinical pharmacology information
  • How the drug is supplied
  • How long the drug takes to work

Format Recommendations

The FDA's recommended formats for presenting risk information to consumers in the consumer brief summary are as follows:

  • A Prescription Drug Facts Box similar to the Over-the-Counter Drug Facts Box
  • A Question and Answer format

Comparison of the 2004 Draft Guidance and the 2015 Revised Draft Guidance

In the revised Draft Guidance, the FDA expanded the application of the 2004 draft guidance to biologics and consumer-directed promotional labeling, and changed its position regarding how firms should present risk information.  In the 2004 version, the FDA offered firms three options for presenting risk information in consumer-directed print advertisements:

  • Present all risk information from the FDA-approved professional labeling
  • Reproduce FDA-approved patient labeling, in its entirety or without less important risk information
  • Provide risk information that would be appropriate for the FDA-approved Highlights of Prescribing Information

Although the FDA emphasized that it would not object to advertisements that omitted less important risk information in 2004, the agency still endorsed the presentation or reproduction of all risk information in consumer-directed advertisements.

In contrast, the 2015 Draft Guidance strongly recommends against the inclusion of all risk information and verbatim reproductions of risk information.  Both versions of the Draft Guidance similarly discourage firms from using small type and scientific, technical and medical terms that are less likely to be understood by consumers.

Although the 2004 draft guidance did not provide specific "research-tested" formats for presenting risk information, it contained similar recommendations to the 2015 Draft Guidance regarding content.  For example, the 2004 draft guidance recommended that firms include a reminder that the information presented is not comprehensive and a toll-free number or website where consumers could find additional information.  The 2015 Draft Guidance additionally recommends that each advertisement suggest that the consumer speak with his or her health care provider or pharmacist.

Implications for Regulated Manufacturers, Packers and Distributors

The agency's approach is a constructive effort to optimize readability and consumer comprehension of important risk information presented in prescription drug materials.  By offering an alternative to the inclusion of the entire risk-related section of the FDA-approved package insert in print advertisements or the full package insert in promotional labeling pieces, the revised Draft Guidance offers a new regulatory approach to communicating with consumers in advertising and promotional materials.  However, the revised draft guidance will likely impose new challenges for firms seeking to adapt their overall advertising and promotion program to these changing regulatory enforcement policies, while also mitigating risk with regard to product liability and consumer protection laws.

Comment Deadline

Firms should consider submitting comments regarding the Draft Guidance to the FDA.  Any comments must be submitted by May 11, 2015, in order to be considered by the agency before it begins work on the final guidance document.

FDA Issues Revised Draft Guidance On Disclosures Of Risk Information In Consumer-Friendly Print Advertisements And Promotional Labeling

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions